4Tissue
Enabling Next-Generation Tissue Regeneration

4Tissue is redefining breast reconstruction with its advanced hydrogel tissue mimic technology that enhances the body's natural tissue regeneration process. Delivering natural and long-lasting results, it ushers in a new era of safe, effective and life-affirming solutions for women after battling breast cancer.

“Our hydrogel platform isn’t just about reconstructing tissue, it’s redefining the future of soft-tissue regeneration,” says Dr. An Van Den Bulcke, chief executive officer a.i. and co-founder. “We make it safer, simpler and truly patient-centered.”

Over 60 percent of women undergoing mastectomy in Europe choose reconstruction, yet current treatments are not optimal.

Synthetic implants, though widely used, carry risks such as capsular contracture, implant rupture and potential systemic complications. Their limited lifespan often requires multiple replacement surgeries over a patient’s lifetime. Autologous flap procedures involve complex microsurgery, extended hospital stays of four to seven days, recovery periods lasting six to eight weeks, and visible scarring at both the donor and reconstruction sites. Autologous lipofilling, a process of grafting a patient’s own fat, offers a more natural and minimal invasive alternative, but with significant drawbacks. On average, only around 50 percent of the transferred volume is retained, often requiring two to eight procedures to achieve the desired result. It is assumed that many of the injected cells fail to survive due to factors such as shear stress during injection, leakage, poor integration into the host tissue, and limited nutrient supply at the target site.

4Tissue’s first-in-class, bioresorbable injectable hydrogel transcends these limitations by protecting and anchoring cells. By encapsulating a patient’s own adipose or stem cells within, it significantly enhances initial cell survival and allows the formation of new vasculature, accelerating tissue regeneration. Over approximately six months, the hydrogel gradually resorbs, leaving behind fully natural tissue without any foreign remnants. Because of high cell survival the procedure can be done in one-step with durable, natural results, avoiding the need for repeat interventions, hospitalization and anesthesia. The injectable format also minimises scarring and surgical complexity.

Stored at room temperature in lyophilised form, the bio-interactive, GMP-compliant material can be easily reconstituted and mixed with harvested fat cells in the operating room. This ensures seamless integration into current surgical practice without adding time or complexity, while maintaining safety and consistent operational excellence.

In a preclinical study supporting breast reconstruction, 4Tissue's Class III medical device was mixed with autologous fat and injected into soft tissue defects. Over the three-month study, the hydrogel protected cells from mechanical damage, enhanced neovascularisation and nearly doubled retained volume compared to the lipofilling-only control group.

With its quality-by-design polymer toolbox, 4Tissue can fine-tune its materials to match the needs of a wide range of applications. Its modular hydrogel platform and strategic patent portfolio hold strong potential for broader applications in soft-tissue conditions such as mucosal and skin regeneration and wound treatment. It is also evolving towards 3D printing, enabling precise customisation of mechanical properties and degradation profiles. This paves the way for personalised implants.

While the technology is still in the development phase, 4Tissue's partners, who often function as early adopters of this platform, and co-developers, commend the company’s collaborative spirit. A multidisciplinary team of polymer chemists, surgeons and regulatory experts is at the core of 4Tissue’s innovation, designing solutions tailored to real-world clinical challenges.

With a focus on patient-centered healing, 4Tissue's organisational structure includes dedicated clinical and regulatory leadership and a board of seasoned industry figures. Born from a spin-off of Ghent University, Ghent University Hospital and Vrije Universiteit Brussel, 4Tissue is co-founded by Prof. Phillip Blondeel and Prof. Sandra Van Vlierberghe, leaders in plastic surgery and polymer chemistry, respectively. This blend of deep academic research and real-world clinical expertise makes the breakthrough both scientifically advanced and medically practical.

The deep academic pedigree and strong consortium ties ensure continuous innovation and rapid translation of emerging polymer technologies into clinical practice, with all materials and processes designed to meet ISO and MDR requirements. The growing support from clinicians sets the stage for sustained engagement and future platform adoption.

4Tissue is building a future where recovery is simplified and regeneration is natural.